Compare NSYS & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSYS | MIRA |
|---|---|---|
| Founded | 1981 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 43.7M |
| IPO Year | 1996 | 2023 |
| Metric | NSYS | MIRA |
|---|---|---|
| Price | $16.18 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.6K | ★ 123.9K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,371,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $6.50 | $0.90 |
| 52 Week High | $18.01 | $2.45 |
| Indicator | NSYS | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 44.02 |
| Support Level | $8.62 | $0.91 |
| Resistance Level | $18.01 | $1.22 |
| Average True Range (ATR) | 1.35 | 0.06 |
| MACD | 0.23 | -0.00 |
| Stochastic Oscillator | 87.90 | 8.04 |
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.